Vall d'Hebron Institute of Oncology (VHIO)
Mafalda Oliveira is a prominent medical professional with extensive experience in oncology, currently serving as President and Executive Board Member of SOLTI since September 2012, while also holding positions as Senior Consultant and Attending Physician at Vall d'Hebron Barcelona Hospital Campus since September 2015. Oliveira has a strong background in breast cancer research, having worked as an Attending Physician and Clinical Investigator at the Vall d’Hebron Institute of Oncology since April 2011. Prior roles include Clinical Research Fellow at both Vall d'Hebron and SOLTI, and fellow in Medical Oncology at IPO Lisboa. Mafalda Oliveira holds a PhD in Medicine and a Master's degree in Applied Clinical Research from Universitat Autònoma de Barcelona, complemented by an MD from the University of Lisbon.
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.